Valuation: Moderna, Inc.

Market Cap 32.46B 28.43B 26.18B 24.3B 46.15B 3,096B 46.77B 313B 122B 1,520B 122B 119B 5,269B P/E 2026 *
-9.48x
P/E 2027 * -17.4x
Enterprise Value 28.85B 25.27B 23.27B 21.6B 41.02B 2,752B 41.58B 279B 108B 1,351B 108B 106B 4,684B EV / Sales 2026 *
13.8x
EV / Sales 2027 * 11.9x
Free-Float
92.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Moderna, Inc.

1 day+67.97%
3 months-8.23%
6 months+77.95%
Current year+77.95%
Current year 42.48
Extreme 42.485
50.31
1 year 20.8
Extreme 20.8
50.31
3 years 20.8
Extreme 20.8
149.5
5 years 20.8
Extreme 20.8
263.48
10 years 20.8
Extreme 20.8
263.48
Manager TitleAgeSince
Chief Executive Officer 54 2011-02-28
Director of Finance/CFO 49 2022-09-05
President 50 2024-10-31
Director TitleAgeSince
Chairman 63 2012-01-31
Director/Board Member 54 2011-02-28
Director/Board Member 69 2019-12-10
Change 5-day change 1-year change 3-year change Capi.($)
+67.94%0.00% - - 32.46B
-0.68%+2.85%+18.72%-7.81% 66.11B
-0.20%-3.05%+49.50%+224.23% 55.3B
-1.13%+40.50%+40.50%+40.50% 42.44B
-0.21%+8.04%-50.01%-53.55% 41.28B
-3.54%-3.77%+56.89%-26.85% 30.78B
-1.06%+0.84%+68.91%+83.93% 23.1B
-3.65%+9.55%+5.63%+188.26% 20.06B
-0.38%+3.77%+67.62%+135.69% 17.19B
+0.73%+7.97%+76.74%+357.35% 15.23B
Average +5.80%+4.20%+37.17%+104.64% 34.61B
Weighted average by Cap. +5.51%+2.85%+30.23%+77.22%

Financials

2026 *2027 *
Net sales 2.09B 1.83B 1.69B 1.57B 2.98B 200B 3.02B 20.21B 7.86B 97.99B 7.86B 7.69B 340B 2.53B 2.21B 2.04B 1.89B 3.6B 241B 3.64B 24.42B 9.5B 118B 9.5B 9.29B 411B
Net income -3.4B -2.98B -2.74B -2.54B -4.83B -324B -4.9B -32.8B -12.77B -159B -12.76B -12.48B -552B -1.82B -1.6B -1.47B -1.37B -2.59B -174B -2.63B -17.62B -6.86B -85.43B -6.85B -6.7B -296B
Net Debt -3.61B -3.16B -2.91B -2.7B -5.13B -344B -5.2B -34.82B -13.55B -169B -13.54B -13.24B -585B -2.27B -1.99B -1.84B -1.7B -3.23B -217B -3.28B -21.97B -8.55B -107B -8.54B -8.36B -369B
Logo Moderna, Inc.
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).
Employees
4,700
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
24
Last Close Price
81.80USD
Average target price
45.85USD
Spread / Average Target
-43.95%

Quarterly revenue - Rate of surprise